SGLT-2 inhibitors in frail patients with heart failure
Author:
- Olivier Luc CharansonneyOCOlivier Luc Charansonney
- 5 February 2022
- journal article
- editorial
- Published by Elsevier in International Journal of Cardiology
- Vol. 352, 102-103
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- A Meta-Analysis of the Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Heart Failure and Preserved Ejection FractionThe American Journal of Cardiology, 2022
- Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved TrialCirculation, 2021
- Effects of SGLT2 inhibitors on cardiovascular, renal, and major safety outcomes in heart failure: A meta-analysis of randomized controlled trialsInternational Journal of Cardiology, 2021
- Gender differences in the prevalence of frailty in heart failure: A systematic review and meta-analysisInternational Journal of Cardiology, 2021
- Baseline Characteristics of Patients with Heart Failure with Preserved Ejection Fraction in the EMPEROR-Preserved TrialEuropean Journal of Heart Failure, 2020
- The prevalence of frailty in heart failure: A systematic review and meta-analysisInternational Journal of Cardiology, 2017
- Frailty measurement in research and clinical practice: A reviewEuropean Journal of Internal Medicine, 2016
- Preventing Frail HealthClinics in Geriatric Medicine, 1992